Day 1 Conference at analytica Lab India 2026
Alongside the industrial trade floor at HITEX Exhibition Centre, the first-floor conference halls of Hall 5 hosted the three-day technical conference of analytica Lab India 2026. The opening day, curated in collaboration with the Indian Analytical Instruments Association (IAIA), brought together principal scientists and quality heads from across India’s pharmaceutical and biologics sector to address the analytical methodologies and regulatory frameworks required to scale complex therapeutics in global markets — a session series that unfolded against a backdrop of escalating scrutiny from the US FDA, the European Medicines Agency, and the World Health Organization as Indian manufacturers move from conventional generics into biosimilars, synthetic peptides, conjugated vaccines, and advanced therapy medicinal products.
Eight speakers anchored the day’s technical program: Dr. Mrunal Jaywant of the U.S. Pharmacopeia on nitrosamine risk assessment; Dr. Vaibhav Dubey of Sun Pharmaceutical Industries on global branded generics; D Mahesh of Indian Immunologicals on vaccine and ATMP quality control; Dr. Abhay Gupta of Chemo India Formulations on high-impact formulations; Dr. K. Balakumaran of Aurigene Pharmaceutical Services on scientific services and Global Capability Centres; Dr. Ramesh Thippani of DRHP Testing Solutions on medical device testing; and Ramchandra Reddy of MSN Labs and Dr. Peddi Reddy of the Serum Institute of India on large-molecule analytical R&D and next-wave bioprocessing.
Mitigating NDSRIs
Dr. Mrunal Jaywant, Vice President (R&D) at the U.S. Pharmacopeia, opened the scientific proceedings with one of the industry’s most intricate regulatory hurdles: Nitrosamine Drug Substance-Related Impurities (NDSRIs). With global health agencies enforcing acceptable intake limits calculated in low nanograms per day — often based on the Carcinogenic Potency Categorization Approach — routine chromatography lacks the sensitivity required for compliance. Dr. Jaywant demonstrated the newly updated USP Nitrosamine Risk Assessment Tool, showing how computational QSAR models can be paired with empirical testing workflows, and detailed the technical necessity of tandem mass spectrometry — both LC-MS/MS and GC-MS/MS using triple-quadrupole and high-resolution accurate-mass systems — for NDSRI quantification in finished matrices.
A central takeaway was her warning on artifactual formation: trace nitrites present in common excipients, such as microcrystalline cellulose or povidone, can react with secondary or tertiary amines during standard sample preparation, falsely inflating measured contamination levels. She presented validated method parameters using scavenging agents and low-temperature extractions to guard against this.
Complex Generics & Supramolecular Bioequivalence
Dr. Vaibhav Dubey, Senior General Manager at Sun Pharmaceutical Industries, followed with an analysis of the analytical challenges surrounding branded, complex generics. As standard small-molecule margins erode, Indian pharmaceutical majors are shifting capital toward liposomal suspensions, polymeric nanoparticles, and drug-device combination products. Dr. Dubey stressed that establishing bioequivalence for these systems cannot rely solely on traditional plasma concentration-time curves; regulators require detailed physical characterization to prove sameness in supramolecular structure. He illustrated the use of multi-nuclear NMR spectroscopy to confirm drug encapsulation states, Dynamic Light Scattering paired with nanoparticle tracking analysis for size-distribution measurement, and specialized USP Apparatus 4 flow-through cell dissolution methods to capture true release profiles in bio-relevant media.
Biologics, Vaccines, and Continuous Manufacturing
D Mahesh, General Manager–HBI QC at Indian Immunologicals Limited, presented the quality control architecture supporting the subcontinent’s vaccine sector. Addressing recombinant viral vectors, virus-like particles, and mRNA delivery systems, he detailed the shift away from slow biological potency assays toward biophysical and molecular methods — including digital droplet PCR for absolute viral genome titration, capillary electrophoresis for mRNA purity assessment, and analytical ultracentrifugation to differentiate empty from full capsids.
Dr. Abhay Gupta, General Manager at Chemo India Formulations, moved the discussion into formulation manufacturing, presenting case studies on continuous manufacturing lines governed by Process Analytical Technology. By integrating in-line near-infrared probes and Raman spectroscopy within high-shear blenders and compression feed frames, he showed how analytical testing shifts from a delayed post-tableting checkpoint to continuous, real-time quality assurance.
Outsourcing, Devices & Large-Molecule Characterization
The afternoon sessions broadened into outsourcing and medical devices. Dr. K. Balakumaran, Group Leader–Analytical R&D at Aurigene Pharmaceutical Services, outlined how Indian contract research and manufacturing organizations are transforming into high-value Global Capability Centres handling complex characterization for overseas innovators. Dr. Ramesh Thippani, Director at DRHP Testing Solutions, detailed testing requirements under India’s revised Medical Device Rules, emphasizing that high-risk Class C and D devices require comprehensive extractable and leachable screening using Orbitrap mass spectrometry alongside ISO 10993-compliant biocompatibility testing.
Ramchandra Reddy, Senior General Manager–FAR&D at MSN Labs, and Dr. Peddi Reddy, General Manager for mAbs & Viral Vectors at the Serum Institute of India, closed the day by demonstrating how high-resolution mass spectrometry and automated continuous sampling are essential for monitoring monoclonal antibody charge variants and preventing proteolytic degradation during upstream biomanufacturing — Reddy’s peptide-mapping and intact-mass work on one side, Peddi Reddy’s continuous perfusion bioreactor monitoring on the other, framing the day’s closing argument that large-molecule characterization now sits at the center of India’s biomanufacturing ambitions.




